ALK and non-small cell lung carcinoma: This concerned three appraisals for second line treatment of ALK positive NSCLC (TA395 in 2016, TA571 in 2019, and TA628 in 2020) and two appraisals for first line treatment of ROS1 positive NSCLC (TA529 in 2018 and TA643 in 2020).